Sample from ASH 2022, CALR antibody

[EPguy]

Progress on the immune therapy we've discussed:

"In a mouse model of essential thrombocythemia, INCA033989 selectively decreased levels of mutant CALR-positive platelets, re-established normal megakaryopoiesis, and selectively targeted mutant CALR disease-initiating clones. "

cancertherapyadvisor.com/ho...

As expected it's directed to CALR which is the easiest and first candidate for such therapy as discussed in prior posts.

[dbus1417]

God is good. Thank you for this news. I pray other mutations have breakthroughs like this.

At 39 years old I feel more and more confident all the time that I won’t have my mpn (ET - CALR) forever. 🤙